Table 3.
Multivariate analysis for tumor downstaging
| Variable | OR (95% CI) | p-value |
|---|---|---|
| Gender (male vs. female) | 1.391 (0.880–2.199) | 0.165 |
| Age >60 yr (≤60 vs. >60) | 0.946 (0.615–1.456) | 0.806 |
| Distance from anal verge (≤4 cm vs. >4 cm) | 1.082 (0.679–1.723) | 0.743 |
| Clinical TNM stage | ||
| (I vs. II) | 0.742 (0.294–1.874) | 0.535 |
| (I vs. III) | 1.124 (0.685–1.844) | 0.649 |
| Histological grade (low grade vs. high grade) | 3.139 (1.467–6.720) | 0.003* |
| Circumferential extent (≤60% vs. >60%) | 1.618 (1.042–2.513) | 0.039* |
| Pretreatment CEA level (≤5 ng/mL vs. >5 ng/mL) | 1.405 (0.871–2.266) | 0.160 |
| Chemotherapy regimen (5-FU vs. capecitabine) | 0.771 (0.500–1.188) | 0.248 |
| Post-CRT leukocyte count (≤3730/uL vs. >3730/uL) | 2.698 (1.547–4.706) | <0.001* |
OR, odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen; FU, fluorouracil; CRT, chemoradiotherapy.
*
p<0.05.